TB

Sanofi CEO Paul Hudson announced on Tuesday the creation of a nonprofit unit, Sanofi Global Health, which will provide 40 lower-income countries with access to 30 of the company’s “most essential medicines,” including cardiovascular, diabetes, tuberculosis, malaria and cancer treatments.

An accompanying press release said Sanofi Global Health will be the cornerstone of the Paris-based company’s corporate social responsibility strategy for “access to medicines, support for vulnerable…

Médecins Sans Frontières (MSF) used Wednesday’s World Tuberculosis Day to announce that its candidate six-month, all-oral regimen is superior to locally accepted 9-20-month care standards for multidrug-resistant TB. MSF has now stopped enrollment in the Phase 2/3 trial of the treatment—containing bedaquiline, linezolid, moxifloxacin and pretomanid—based on an independent data safety and monitoring board recommendation, the press release said. MSF said it plans to share its data with WHO “as…

TB Alliance announced a collaboration Monday with ZebiAI to discover, develop and deliver “better, faster-acting and affordable” tuberculosis drugs using the Massachusetts-based company’s machine learning platform.

The project joins a trend in global health: artificial intelligence-driven discoveries in recent years include potential Chagas treatments identified through a Drugs for Neglected Diseases initiative collaboration and an MIT-discovered compound that kills a broad range of…

The IMPAACT4TB consortium announced Wednesday that it will roll out a new, patient-friendly preventive tuberculosis therapy in five high-burden countries, beginning in February.

Led by African NGO the Aurum Institute (with funding from Unitaid), the program will provide a fixed-dose combination of “3HP”—a short-course TB treatment combining rifapentine and isoniazid—to Ethiopia, Ghana, Kenya, Mozambique and Zimbabwe. An agreement between manufacturer Macleods, Unitaid and the Clinton…

GSK and Novartis jointly pledged funding on Tuesday to research the link between genetic diversity and response to malaria and tuberculosis drugs in African patients.

A joint press release said the companies will invest a combined $3.6 million over five years in their Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT) collaboration, which will release all collected data to the public.

GRADIENT is inviting researchers across Africa to…

Amgen and Medicines Development for Global Health (MDGH) announced last week that the Australia-based nonprofit will take over AMG 634—Amgen’s investigational treatment for tuberculosis and erythema nodosum leprosum, a complication from leprosy.

According to the press release, Amgen will continue to support two ongoing Phase 2 trials as part of the handoff. MDGH will assume full responsibility for any further development and commercialization of AMG 634.

The California-based…

Mentions:

The TB Alliance announced Tuesday the dosing of the first participant in Phase 1 trials of TBAJ-587, its novel diarylquinoline compound that demonstrated a superior preclinical profile against M. tuberculosis, according to the press release.

In other TB news, the UN-backed Medicines Patent Pool announced last week that it has sublicensed patents and know-how relating to the investigational antibiotic sutezolid to the Gates Medical Research Institute. The sublicense gives access to…

UK-based Exscientia announced last week a $4.2 million drug discovery grant from the Gates Foundation to use the company’s AI-driven platforms to find small molecule candidates for malaria, non-hormonal contraceptives and tuberculosis.

Exscientia has drug discovery collaborations with several companies, including Bayer, Bristol Myers Squibb, GSK and Sanofi.

Two different four-month treatment regimens for tuberculosis proved non-inferior to the standard six-month regimens for their trial populations, according to Phase 3 results presented separately at last week’s Union World Conference on Lung Health.

First, a 13-country, U.S. Centers for Disease Control and Prevention-led trial of over 2,500 participants with drug-susceptible TB found that an abbreviated regimen—which modified the standard treatment (a combination of isoniazid, rifampin…

Mentions:

Dartmouth University announced yesterday that it will move its DAR-901 inactivated whole-cell TB vaccine candidate to Phase 3. A Phase 2b study found the shot safe and well-tolerated, according to an article published this week in Vaccine.

In a press release, Dartmouth described the study as a novel “Prevention of Infection” trial, noting that TB infection “is favorable in most people” because it provides immunity against progression to TB disease. The Phase 2b trial found no…